NCT03048422: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 1 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03048422 |
|---|---|
| Title | Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 19, 2018 |
| Completion date | Oct. 3, 2020 |
| Required reporting date | Oct. 3, 2021, midnight |
| Actual reporting date | Oct. 4, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 1 |